Viz.ai

AI Healthcare Tools AI Research & Education Tools

↳AI Medical Imaging & Diagnostics ↳AI Medical Research & Clinical Decision Support

Custom

AI care coordination platform for stroke, PE, and aortic disease — FDA-cleared algorithms alerting care teams in minutes

Not yet rated

Released 2016

Visit Website

Gallery

4 items

VIDEO

About Viz.ai

Viz.ai is the leading AI care coordination platform for time-sensitive medical conditions, deployed in over 1,000 hospitals across the U.S. and Europe. Co-founded in 2016 by neurosurgeon Dr. Chris Mansi and ML researcher David Golan, Viz.ai was built to solve one of medicine's most urgent problems: the deadly delays in diagnosing and treating acute stroke. With 12 FDA-cleared algorithms and backing from Google Ventures, Kleiner Perkins, and Tiger Global ($289M raised), Viz.ai has transformed acute care workflows across neurology, cardiology, and pulmonology.

When a CT scan enters the hospital system, Viz.ai's AI analyzes it in real time, detecting critical findings like large vessel occlusion (LVO) stroke, pulmonary embolism, and aortic dissection within minutes. The entire care team — ED physician, neurologist, interventionalist, and transfer team — is simultaneously alerted via mobile app with imaging attached, eliminating the traditional phone-tag delays that cost patients millions of neurons per minute. Clinical data from ISC 2026 shows Viz.ai delivers a 44% reduction in door-in-door-out (DIDO) times for LVO stroke patients at regional hospitals.

Viz.ai is ideal for stroke centers, comprehensive cardiac centers, pulmonary embolism response teams (PERTs), and health systems seeking to reduce time-to-treatment for acute conditions — and it is the only AI platform in its category with a Medicare NTAP reimbursement designation, providing hospitals with an additional ~$1,040 per qualifying patient encounter.

Key Features

12 FDA-cleared AI algorithms for stroke, PE, aortic disease, and hypertrophic cardiomyopathy
Real-time CT scan analysis detecting LVO strokes in under 6 minutes
Automated mobile alerts to entire care team — neurologist, ED, interventionalist — simultaneously
HIPAA-compliant mobile care coordination platform with image viewing on smartphones
44% reduction in door-in-door-out (DIDO) time for LVO stroke patients
Medicare New Technology Add-on Payment (NTAP) recognized — CMS reimbursement pathway
Deployed across 1,000+ hospitals in the U.S. and Europe
Aortic disease module covering AAA, aortic dissection, and pulmonary embolism workflows
Integrated care coordination — patient referrals, pre-scan sharing, and transfer workflows
Backed by Google Ventures, Kleiner Perkins, and Tiger Global — $289M raised

Pros

12 FDA-cleared algorithms — broadest acute-condition AI portfolio in its class
Medicare NTAP reimbursement pathway — unique among AI imaging platforms
44% reduction in DIDO times for stroke patients — peer-reviewed clinical evidence (ISC 2026)
1,000+ hospital deployments across U.S. and Europe
Backed by Google Ventures, Kleiner Perkins, and Tiger Global — $289M raised
Simultaneous mobile alerts to full care team — no phone-tag delays
Expands from neurology to cardiology and pulmonology in one unified platform

Cons

Enterprise-only pricing — no self-serve or small clinic access
No published pricing — all contracts are custom
Primarily focused on acute/time-sensitive conditions — not general radiology reads
Requires integration with existing hospital imaging infrastructure
Implementation and onboarding take time for large multi-site systems

Pricing

Viz.ai operates exclusively on custom enterprise contracts with hospitals, health systems, and imaging networks. There is no published pricing or self-serve access.

Pricing is negotiated based on hospital type, imaging volume, number of conditions covered, and multi-site deployment needs. Viz.ai's Medicare NTAP designation provides hospitals with an additional reimbursement of approximately $1,040 per qualifying patient encounter, partially offsetting platform costs.

Contact Viz.ai through viz.ai to schedule a demo and begin enterprise procurement discussions.

Claim Verified Creator Badge

Are you the founder of Viz.ai? Display this listing's verified badge on your website to show your customers that your product has been vetted and listed on AI Central Resources.

HTML Embed Code

<a href="https://www.aicentralresources.com/tool/vizai" target="_blank" rel="noopener">
  <img src="https://www.aicentralresources.com/badges/featured-badge-dark.svg" alt="Featured on AICentralResources" width="200" height="54" style="border: none;" />
</a>

* Place this HTML snippet in your website's footer, landing page, or press section. This creates a search-friendly backlink directly to your verification page.

Connect with Viz.ai

X (Twitter)LinkedIn

Frequently Asked Questions

Viz.ai automatically analyzes CT scans for suspected large vessel occlusion (LVO) strokes and other critical conditions, then alerts the entire care team — including the stroke neurologist, ED physician, and interventionalist — via mobile app within minutes, enabling faster transfer and treatment.

Viz.ai has 12 FDA-cleared AI algorithms covering stroke (LVO, ICH), pulmonary embolism, aortic disease (aneurysm, dissection), hypertrophic cardiomyopathy, and other time-sensitive conditions.

Yes — Viz.ai received a Medicare New Technology Add-on Payment (NTAP) designation from CMS, providing hospitals with an additional reimbursement of approximately $1,040 per use for treating patients with suspected stroke using the Viz.ai platform.

Viz.ai is deployed in over 1,000 hospitals across the U.S. and Europe. Its care coordination platform has helped hospitals achieve up to 44% reduction in door-in-door-out (DIDO) times for LVO stroke patients.

Viz.ai was co-founded in 2016 by Dr. Chris Mansi, a neurosurgeon, and David Golan, a machine learning researcher, who met at Stanford. They built the platform to address the life-threatening delays in stroke diagnosis and treatment they observed in clinical practice.